Adam Green, MD | Assistant Professor of Pediatrics | Attending Physician in Pediatric Neuro-Oncology/Oncology
We recently received an update from Adam Green, MD | Assistant Professor of Pediatrics at the University of Colorado School of Medicine and Attending, Physician, in Pediatric Neuro-Oncology/Oncology at Children’s Hospital Colorado on the research that TeamConnor funded in 2013 with a $50,000 grant. We originally funded his research at Dana-Farber Cancer Institute at Boston Children’s Hospital, and he then transitioned the research when he joined the Children’s Hospital in Colorado. We applaud Dr. Green with this research and the findings of his research in the published publication.
I wanted to let you know about the attached paper we published this month on research that was partially funded by our TeamConnor Community Impact grant, which is acknowledged in the paper. Selinexor, a novel cancer drug that works by inhibiting a protein that exports tumor suppressor proteins (the brakes in cells) from the nucleus where they function, was recently FDA approved for an adult cancer called multiple myeloma and is in clinical trials for other cancers including high-grade glioma (HGG), a leading cause of cancer death in children. We studied patient-derived cell lines and mouse models to understand how Selinexor works in HGG. We found that Selinexor decreases tumor proliferation and increases cell death by increasing the expression of another protein called NGFR that blocks activation of an important cancer pathway called NF-kB. This mechanism of action suggests potential combination therapies, including proteasome inhibition, that may work with Selinexor against HGG, which we begin to investigate here. The first pediatric clinical trial of Selinexor in childhood brain and solid tumors, which I am leading, is still open nationally. This work will help us determine which patients may benefit most from this medicine and how to combine it with other chemotherapy medicines to make it more effective.
Click download to read the article.
You must be logged in to post a comment.
Sign up to comment in the forums, on posts, and receive our newsletters.